Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
This map shows the geographic impact of Bunn Pa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bunn Pa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bunn Pa more than expected).
This network shows the impact of papers produced by Bunn Pa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bunn Pa. The network helps show where Bunn Pa may publish in the future.
Co-authorship network of co-authors of Bunn Pa
This figure shows the co-authorship network connecting the top 25 collaborators of Bunn Pa.
A scholar is included among the top collaborators of Bunn Pa based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Bunn Pa. Bunn Pa is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Pa, Bunn. (1999). Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer.. PubMed. 26(1 Suppl 4). 25–30.14 indexed citations
2.
Pa, Bunn. (1998). Cancer and acquired immunodeficiency syndrome wasting syndromes: current and future therapies.. PubMed. 25(2 Suppl 6). 1–3.6 indexed citations
3.
Pa, Bunn, et al.. (1997). Overview of chemotherapy for small cell lung cancer.. PubMed. 24(2 Suppl 7). S7–69.48 indexed citations
4.
Pa, Bunn. (1997). The emerging role of gemcitabine in lung cancer.. PubMed. 24(3 Suppl 8). S8–1.1 indexed citations
5.
Pa, Bunn. (1996). Current therapy of small cell lung cancer.. PubMed. 23(6 Suppl 16). 1–4.2 indexed citations
6.
Pa, Bunn. (1996). The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer.. PubMed. 23(6 Suppl 16). 18–25.10 indexed citations
7.
Pa, Bunn, et al.. (1992). Effects of neuropeptides on human lung and breast cancer cells.. PubMed. 145–51.19 indexed citations
Pa, Bunn, et al.. (1979). Ultrastructural appearance of cutaneous T cell lymphomas in skin, lymph nodes, and peripheral blood.. PubMed. 63(4). 565–70.26 indexed citations
11.
Pa, Bunn, et al.. (1978). Central nervous system metastases in small cell bronchogenic carcinoma.. PubMed. 5(3). 314–22.107 indexed citations
12.
Pa, Bunn. (1966). Present power potions for pestilences and plagues.. PubMed. 77. 1–10.1 indexed citations
Pa, Bunn, et al.. (1965). Immunoglobulin responses to bacterial endocarditis.. PubMed. 5. 59–63.7 indexed citations
15.
Pa, Bunn. (1964). ALLERGIC REACTIONS TO PENICILLINS, NEW AND OLD.. PubMed. 10. 302–10.4 indexed citations
16.
Pa, Bunn. (1964). MANAGEMENT AND ENDOCARDITIS WITH SYNTHETIC PENICILLINS.. PubMed. 10. 263–7.3 indexed citations
17.
Pa, Bunn, et al.. (1961). Comparison of properdin titers in sera of normal subjects and patients with leukemia and lymphoma by zymosan and bacteriophage assavs.. PubMed. 57. 420–7.2 indexed citations
18.
Pa, Bunn, et al.. (1955). Pharmacologic properties of various antimicrobial agents with particular reference to common dosage scheduling.. PubMed. 55(24). 3607–17.1 indexed citations
19.
Pa, Bunn, et al.. (1953). Treatment of pylephlebitis secondary to acute appendicitis.. PubMed. 53(24). 3007–10.2 indexed citations
20.
Pa, Bunn. (1952). Present trends in the treatment of the pneumonias.. PubMed. 52(16). 2005–9.1 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.